OGT Launches First Fusion MRD NGS Panel for AML to Expand Fusion Detection at MRD-Level Sensitivity

OGT launches first Fusion MRD NGS Panel for AML

OGT, a provider of genomic research and diagnostic solutions, has announced the launch of the SureSeq myPanel Myeloid Fusion MRD Panel, the first-to-market dedicated fusion MRD next-generation sequencing (NGS) panel for acute myeloid leukaemia (AML).

OGT Launches NGS Panel to Detect Residual Disease in Acute Myeloid Leukemia

The RNA-based panel detects leukemia-associated gene fusions at levels as low as 1% tumor cells, offering another approach to monitoring residual disease.

OGT Launches First Fusion MRD NGS Panel for AML to Expand Fusion Detection at MRD-Level Sensitivity

OGT, a leading global provider of genomic research and diagnostic solutions, today announced the launch of the SureSeq™ myPanel Myeloid Fusion MRD Panel, the first-to-market dedicated fusion MRD next-generation sequencing (NGS) panel for acute myeloid leukemia (AML).